Detail page

Knowledge Web

Person

Matthias Eder (1979-)

Name	Matthias Eder
Time	1979- (Date of birth and death)
Place	Heidelberg (Geburtsort) Freiburg im Breisgau (Wirkungsort) Deutschland
Academic degree	Prof. Dr. sc. hum.
Related	Albert-Ludwigs-Universität Freiburg. Medizinische Fakultät (2017-) Universität Heidelberg. Medizinische Fakultät (Lehrbeauftragter) (-2017) Biotechnologie (Studienfach)
Further information	Diss. Medizinische Fakultät der Univ. Heidelberg
Record type	Person
GND-Identifier	140263217
Record ID	140263217
Involved in show all 2-[18F]F-p-aminobenzoic acid specifically detects infective endocarditis in positron emission tomography Dual-labeled small peptides in cancer imaging and fluorescence-guided surgery: progress and future perspectives Highly efficient puromycin linker synthesis and peptide bicyclization in cDNA-display targeting EpCAM Highly efficient puromycin linker synthesis and peptide bicyclization in cDNA-display targeting EpCAM Changes in prostate-specific membrane antigen (PSMA) expression following ionizing irradiation - Implications for prostate cancer therapy Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside Identification of low molecular weight peptides targeting EpCAM and CD44v6 Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer A new class of PSMA-617-based hybrid molecules for preoperative imaging and intraoperative fluorescence navigation of prostate cancer Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer Heterobivalente Radiopharmaka um die intratumorale Heterogenität zu adressieren PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) [177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography Multimodal imaging for radiation therapy planning in patients with primary prostate cancer 68Ga-markierte rekombinante Antikörperfragmente für die molekulare Charakterisierung und Lokalisation von Tumoren mittels Positronen-Emissionstomographie

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Matthias Eder (1979-)

2-[18F]F-p-aminobenzoic acid specifically detects infective endocarditis in positron emission tomography

Dual-labeled small peptides in cancer imaging and fluorescence-guided surgery: progress and future perspectives

Highly efficient puromycin linker synthesis and peptide bicyclization in cDNA-display targeting EpCAM

Highly efficient puromycin linker synthesis and peptide bicyclization in cDNA-display targeting EpCAM

Changes in prostate-specific membrane antigen (PSMA) expression following ionizing irradiation - Implications for prostate cancer therapy

Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside

Identification of low molecular weight peptides targeting EpCAM and CD44v6

Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies

[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer

A new class of PSMA-617-based hybrid molecules for preoperative imaging and intraoperative fluorescence navigation of prostate cancer

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging

[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

Heterobivalente Radiopharmaka um die intratumorale Heterogenität zu adressieren

PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

[177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography

Multimodal imaging for radiation therapy planning in patients with primary prostate cancer

68Ga-markierte rekombinante Antikörperfragmente für die molekulare Charakterisierung und Lokalisation von Tumoren mittels Positronen-Emissionstomographie